Special Issue

Integrative Multi-Omics for Novel Clinical Insights

Message from the Guest Editor

Recent advances in high-throughput sequencing and other omics technologies have made it possible to generate a tremendous amount of biomolecular data on clinical cohorts. Moreover, it has been shown in a number of contexts that signatures combining multiple omics data types outperform single-analyte- or single-omic-based classifiers. Significant challenges remain, as the computational tools for integrating these diverse data types are still limited, and the interpretation of complex multi-omic datasets can be challenging. This Special Issue will showcase novel basic, clinical, and in silico research that leverages the integration of multiple omics data types (e.g., genomics, proteomics, epigenomics, metabolomics, microbiomics, etc.) to elucidate the biology underlying clinical disease phenotypes (e.g. cancer, diabetes, neurological disease, etc.). Review articles surveying existing multi-omics research and methodology will also be featured.

Guest Editor

Dr. Brian Piening
Earle A. Chiles Research Institute, Division of Providence Cancer Institute, 4805 NE Glisan St., Suite 2N88, Portland, OR 97213, USA

Deadline for manuscript submissions

closed (20 November 2020)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/43762

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

MDPI

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).

MDPI